Bristol Myers Squibb has claimed another success from its CELMoD program.

The oral protein degrader mezigdomide cleared the Phase 3 portion of an open-label study called SUCCESSOR-2 in relapsed or refractory multiple myeloma, the company …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844